ONCOLYTICS BIOTECH INCORPORATED (OTCMKTS:ONCYF) had an increase of 13.93% in short interest. ONCYF’s SI was 305,000 shares in December as released by FINRA. Its up 13.93% from 267,700 shares previously. With 166,400 avg volume, 2 days are for ONCOLYTICS BIOTECH INCORPORATED (OTCMKTS:ONCYF)’s short sellers to cover ONCYF’s short positions. The stock increased 2.77% or $0.0148 during the last trading session, reaching $0.5497. About 36,888 shares traded. Oncolytics Biotech Inc. (OTCMKTS:ONCYF) has 0.00% since December 10, 2016 and is . It has underperformed by 16.70% the S&P500.
Among 10 analysts covering Revance Therapeutics (NASDAQ:RVNC), 9 have Buy rating, 0 Sell and 1 Hold. Therefore 90% are positive. Revance Therapeutics has $54.0 highest and $22 lowest target. $38.75’s average target is 11.83% above currents $34.65 stock price. Revance Therapeutics had 19 analyst reports since August 22, 2015 according to SRatingsIntel. On Tuesday, November 29 the stock rating was initiated by Aegis Capital with “Buy”. The stock of Revance Therapeutics, Inc. (NASDAQ:RVNC) has “Hold” rating given on Tuesday, June 14 by Brean Capital. Mizuho initiated Revance Therapeutics, Inc. (NASDAQ:RVNC) on Thursday, November 16 with “Buy” rating. The stock has “Buy” rating by Barclays Capital on Monday, November 27. Cantor Fitzgerald maintained Revance Therapeutics, Inc. (NASDAQ:RVNC) on Tuesday, October 24 with “Buy” rating. The stock of Revance Therapeutics, Inc. (NASDAQ:RVNC) earned “Hold” rating by Zacks on Saturday, August 22. The rating was maintained by Piper Jaffray on Tuesday, December 5 with “Buy”. The firm earned “Buy” rating on Thursday, July 20 by Cantor Fitzgerald. As per Thursday, November 16, the company rating was maintained by Cantor Fitzgerald. On Thursday, June 8 the stock rating was maintained by Aegis Capital with “Buy”.
Oncolytics Biotech Inc., a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancers. The company has market cap of $77.46 million. The firm is developing REOLYSIN, a systemically administered immune-oncology viral agent for the treatment of solid tumors and hematological malignancies. It currently has negative earnings.
The stock increased 5.80% or $1.9 during the last trading session, reaching $34.65. About 987,350 shares traded or 138.83% up from the average. Revance Therapeutics, Inc. (NASDAQ:RVNC) has risen 20.40% since December 10, 2016 and is uptrending. It has outperformed by 3.70% the S&P500.
Investors sentiment increased to 1.96 in 2017 Q2. Its up 0.99, from 0.97 in 2017Q1. It is positive, as 4 investors sold Revance Therapeutics, Inc. shares while 20 reduced holdings. 15 funds opened positions while 32 raised stakes. 27.29 million shares or 4.87% more from 26.02 million shares in 2017Q1 were reported. Ameriprise Fin Inc reported 0% stake. Fmr Limited Com reported 0% of its portfolio in Revance Therapeutics, Inc. (NASDAQ:RVNC). Essex Invest Management Limited Liability Company stated it has 124,932 shares or 0.47% of all its holdings. Vanguard Grp owns 0% invested in Revance Therapeutics, Inc. (NASDAQ:RVNC) for 931,623 shares. State Of New Jersey Common Pension Fund D invested in 0% or 26,000 shares. Eam Ltd holds 0.15% or 33,897 shares in its portfolio. Jpmorgan Chase And has 0.02% invested in Revance Therapeutics, Inc. (NASDAQ:RVNC) for 3.63M shares. Amer Group Inc Inc stated it has 13,914 shares or 0% of all its holdings. Morgan Stanley reported 179,091 shares. Qs Investors Lc reported 59,259 shares or 0.01% of all its holdings. Art Advsrs Ltd Liability Corp invested in 0.02% or 11,700 shares. Jennison Assoc Limited Liability Corp holds 0.01% of its portfolio in Revance Therapeutics, Inc. (NASDAQ:RVNC) for 378,400 shares. Wells Fargo And Mn holds 0% or 23,284 shares. 3.38 million are owned by Franklin. Essex Woodlands Health Ventures reported 21.92% stake.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.